Table 3 Phenotypic resistance of E. coli isolates by study cycle
Class | Antibiotic | Cycle 1 No. of isolates (%)a n = 277 | Cycle 2 No. of isolates (%) n = 239 | Total No. of Isolates among both cycles (n = 516) |
|---|---|---|---|---|
Cephalosporin/β-lactamase inhibitor | Cefazolin | 277 (100%) | 238 (99.6) | 515 (99.8) |
Ceftazidime | 72 (26.0) | 58 (24.3) | 130 (25.2) | |
Cefepime | 121 (43.7) | 106 (44.4) | 227 (44.0) | |
Cefotaxime | 256 (92.4) | 227 (95.0) | 483 (93.6) | |
Amoxicillin/clavulanic acid | 63 (22.7) | 43 (18.0) | 106 (20.4) | |
Penicillin | Ampicillin | 275 (99.3) | 238 (99.6) | 513 (99.4) |
Aminoglycoside | Gentamycin | 47 (17.0) | 47 (19.7) | 94 (18.2) |
Carbapenem | Imipenem | 2 (0.7) | 1 (0.4) | 3 (0.6) |
Fluroquinolone | Ciprofloxacin | 137 (49.5) | 118 (49.4) | 255 (49.4) |
Tetracycline | Tetracycline | 201 (72.6) | 187 (78.2) | 388 (75.2) |
Folate pathway inhibitors | Trimethoprim-Sulfamethoxazole | 185 (66.8) | 157 (65.7) | 342 (66.3) |
ESBL-producing | 52 (18.8) | 43 (18.0) | 95 (18.4) | |
Multidrug-resistant to three or more classesb | 231 (83.4) | 217 (90.8) | 448 (86.4) | |